SDF-1 Chemokine for Erectile Dysfunction Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for erectile dysfunction, particularly PDE-5 inhibitors, are ineffective for a significant portion of patients, including those with diabetic or spinal cord injuries, and are associated with adverse events and application restrictions, limiting their efficacy and spontaneity of sexual activity.
Innovation Solution
Administration of Stromal Derived Factor-1 (SDF-1) or its functional fragments to the penile tissue to promote neuronal growth and preservation in pelvic ganglion neurons, enhancing penile tissue architecture and vascular function, thereby addressing the underlying causes of erectile dysfunction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If PDE-5 inhibitors are used to treat erectile dysfunction, then erectile function is improved in responsive patients, but treatment effectiveness is limited to less than 70% of patients including those with diabetic or spinal cord injuries
Solution Approach 1:
The patent uses SDF-1 as an intermediary substance that mediates between the administered compound and the target tissue. SDF-1 acts as a mediator to promote endogenous production of nitric oxide and cyclic GMP, thereby indirectly restoring erectile function without directly blocking PDE-5. This intermediary mechanism allows the treatment to work through natural physiological pathways rather than forced pharmacological inhibition.
Solution Approach 2:
The invention enables the patient's own body to restore erectile function through endogenous mechanisms. By administering compounds that stimulate SDF-1 production or activity, the treatment activates the body's natural nitric oxide-cyclic GMP pathway, allowing self-regulation and self-repair of erectile tissue without continuous external pharmacological intervention. This self-service approach addresses the root cause rather than merely masking symptoms.
2Reliability
If PDE-5 inhibitors are administered to achieve erectile function, then physiological response is amplified, but adverse events such as headache, facial flushing, and visual disturbance occur
Solution Approach 1:
The patent converts the harmful over-inhibition of PDE-5 (which causes adverse events) into a beneficial controlled modulation of the nitric oxide-cyclic GMP pathway. Instead of forcing inhibition that disrupts normal physiology, the invention uses SDF-1 to naturally enhance endogenous cyclic GMP production, converting the potential harm of pathway disruption into the benefit of balanced physiological regulation.
Solution Approach 2:
The invention changes the fundamental parameter from pharmacological inhibition intensity to endogenous signaling enhancement. Rather than measuring treatment effect by PDE-5 inhibition level (which correlates with adverse events), the patent measures and optimizes endogenous nitric oxide and cyclic GMP levels, achieving erectile function through parameter changes in natural physiological markers rather than drug concentration.
3Speed
If PDE-5 inhibitors are used for on-demand treatment, then immediate erectile response is achieved, but underlying disease is not cured and treatment spontaneity is limited
Solution Approach 1:
The patent applies preliminary action by restoring the underlying nitric oxide-cyclic GMP pathway function before sexual activity is needed. By administering compounds that stimulate SDF-1 production and enhance endogenous cyclic GMP levels in advance, the treatment prepares the erectile tissue to respond naturally to physiological stimuli, eliminating the need for last-minute pharmacological intervention and enabling spontaneous function.
Solution Approach 2:
The invention establishes continuity of useful action by activating sustained endogenous production of nitric oxide and cyclic GMP through SDF-1 stimulation. Rather than providing transient pharmacological effects that wear off, the treatment creates continuous physiological enhancement that maintains erectile capability over time, allowing spontaneous sexual activity without worrying about drug timing or duration.
Data Source
AI summary
Stromal Derived Factor-1 (SDF-1) is a small, naturally occurring, potent chemokine with inherent angiogenic, neurogenic, anti-apoptotic protein, which is also a potent stem cell chemoattractant, cardiovascular disease, and other metabolic disturbances. The present invention provides methods for treating erectile dysfunction in a male subject comprising administering to the major pelvic ganglion supplying the cavernous nerves subject compositions comprising SDF-1. SDF-1 promotes stem cell activation, to the major pelvic ganglion supplying the cavernous nerves, helps cell preservation, and prevents adverse penile remodeling. It can be administered as a protein or by gene therapy including but not limited to plasmid DNA, viral transduction, or nanoparticle delivery directly to the penis or to the neurovascular bundle or other pelvic nerve structures during the time of surgery, or before injury, or to treat existing erectile dysfunction.